NCT03664336

Completed

Refractory Diffuse Large B-cell Lymphoma

Hospices Civils de Lyon Source

Other study identifiers

Sponsor study identifier

refractory DLBCL

Study Type

observational

Actual enrollment (reported)

104

Locations

1 country

Sites

1

Timeline

Study Start

November 2016

Actual (reported)

Primary Completion

July 2017

Actual (reported)

Study Completion

January 2018

Actual (reported)

Brief Summary

In the rituximab era, one-third of diffuse large B-cell lymphoma (DLBCL) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (IChemo). Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. The investigators performed a retrospective analysis, which included 104 DLBCL patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease. The investigators retrospectively evaluated the outcomes of a cohort of 104 refractory patients according to their patterns of refractoriness and the type of salvage option.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 104 participants
Study completion date: January 2018
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 2016
Actual (reported)
Primary Completion
July 2017
Actual (reported)
Study Completion
January 2018
Actual (reported)
First Submitted
August 22, 2018
Actual (reported)
First Posted
September 10, 2018
Actual (reported)

Last Updated: September 10, 2018
Status Verified: September 2018
Last Update Submitted: September 7, 2018

Conditions

Diffuse Large B-cell Lymphoma

Keywords

diffuse large B-cell lymphomarefractoryrituximab

Outcome Measures

Primary Outcomes (1)

Outcome according to pattern of refractoriness
OS was defined as the time from first relapse, or progression, to death from any cause.
Up to 4 years

Secondary Outcomes (1)

Outcome according to pattern of refractoriness
Up tp 24 months

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Man or woman diagnosed for a DLBCL from January 2002 to January 2017

You may qualify if:

≥18 years of age

Sponsors & Collaborators

Hospices Civils de Lyon
Otherlead

Study Sites (1)

Centre Hospitalier Lyon Sud

Pierre-Bénite, France

MeSH Terms

Conditions

Lymphoma, Large B-Cell, Diffuse

Condition Hierarchy (Ancestors)

Lymphoma, B-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

Clémentine Sarkozy, MD
Hospices Civils de Lyon
PRINCIPAL INVESTIGATOR

Enrollment

104 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 22, 2018

First Posted

September 10, 2018

Study Start

November 2016

Actual (reported)

Unknown

NCT02758925

CyBeR Association in Relapsed/Refractory DLBCL

Phase 2Unknown

NCT02391116

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2Completed

NCT02987400

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Phase 2Completed

NCT02549651

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Phase 1Completed

NCT03383406

A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma

Phase 2Unknown

NCT03123393

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2Terminated

diagnosed with DLBCL at Lyon Sud University Hospital (LSUH) from January 2002 to January 2017

presented with refractory disease in response to front-line therapies

including anthracycline-based chemo and a monoclonal anti-CD20 antibody

You may not qualify if:

Patients with a history of indolent lymphoma,
Patients with a primary central nervous system (CNS) lymphoma or immunosuppression-related lymphoma

Contact the study team to confirm eligibility.

Primary Completion

July 2017

Actual (reported)

Study Completion

January 2018

Actual (reported)

Last Updated

September 10, 2018

Record last verified: 2018-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03664336
Data provider: ClinicalTrials.gov
Source updated: 2018-09-10
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:20:14 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations